Fenben for humans is an antihelmintic drug that debuted in scientific trials some years ago. It’s used to treat parasites, and it’s sold under the brand names Safe-Guard and Panacur. Recently, it’s become popular in the media as a cancer treatment after a story about a man who claimed to have cured his own stage 4 lung cancer by taking fenbendazole for his entire body.
This man’s success prompted other people to share their own stories online, and the discussion has led to many new studies that investigate whether fenbendazole or similar drugs in the benzimidazole family can be effective for a range of different cancers. The latest study to be published in the journal Nature Communications explains that fenbendazole and other anthelmintic drugs have been shown to exhibit antitumor effects against human cancer cells in vitro, and that these properties are linked to the disruption of microtubule dynamics and inhibition of glucose uptake by cancer cells.
The scientists conducted a series of experiments with two different types of human cancer cells, and found that fenbendazole, or FZ, reduced the growth of both of these cell lines. Specifically, the authors report that FZ suppressed apoptosis of actively growing H4IIE hepatocellular carcinoma cells via p21-mediated G1/S arrest, and caused glucose uptake to be inhibited by downregulation of GLUT transporters and hexokinase II. The team also discovered that FZ prevented hepatocellular carcinoma cell invasion, and exhibited anti-proliferative and anti-tumor activity in mouse xenografts.
These results are consistent with previous reports that benzimidazole antihelminthics such as albendazole and mebendazole can kill tumors in mice models. The authors point out that these effects are associated with the disruption of microtubule dynamics and the inhibition of glucose uptake, and suggest that fenbendazole could be used in combination with established cancer treatments to enhance their effectiveness.
Despite the antitumor effects of fenbendazole, there is no evidence that it can prevent recurrence of existing cancers in patients, as Tippens claims. The current treatments are designed to kill only cancer cells that are dividing, and there is no evidence that Fenbendazole would also interfere with this process or prevent the formation of new cancer cells from mutations that occur in the lining of the digestive tract.
The research suggests that there is a need for further studies to assess whether fenbendazole or other drugs in the benzimidazole class might be effective in preventing recurrence of cancers in the stomach, colon and lungs, and perhaps elsewhere. If you are interested in learning more about the role of fenbendazole for humans and other alternatives, speak with an integrative oncology nurse who can give you the latest information about alternative cancer treatments. They can also answer questions about other treatment options for your specific cancer, and help you to determine which one is right for you. They can even provide you with access to a wide selection of supplements that are designed to enhance the effectiveness of your cancer treatment. fenben for humans